These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Mechanism of action of mycophenolate mofetil. Ransom JT Ther Drug Monit; 1995 Dec; 17(6):681-4. PubMed ID: 8588241 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of inosin-5'-monophosphate dehydrogenase activity during maintenance therapy with tacrolimus. Maiguma T; Yosida T; Otsubo K; Okabe Y; Sugitani A; Tanaka M; Oishi R; Teshima D J Clin Pharm Ther; 2010 Feb; 35(1):79-85. PubMed ID: 20175815 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of inosine monophosphate dehydrogenase activity by the plasma of heart transplant recipients receiving mycophenolate mofetil. Griesmacher A; Weigel G; Seebacher G; Mallinger R; Laufer G; Müller MM Adv Exp Med Biol; 1998; 431():537-41. PubMed ID: 9598124 [No Abstract] [Full Text] [Related]
9. Development and application of a high-performance liquid chromatography-based assay for determination of the activity of inosine 5'-monophosphate dehydrogenase in whole blood and isolated mononuclear cells. Albrecht W; Storck M; Pfetsch E; Martin W; Abendroth D Ther Drug Monit; 2000 Jun; 22(3):283-94. PubMed ID: 10850395 [TBL] [Abstract][Full Text] [Related]
10. Immunosuppressive and other effects of mycophenolic acid and an ester prodrug, mycophenolate mofetil. Allison AC; Eugui EM Immunol Rev; 1993 Dec; 136():5-28. PubMed ID: 7907572 [No Abstract] [Full Text] [Related]
11. No relevant pharmacokinetic interaction between pantoprazole and mycophenolate in renal transplant patients: a randomized crossover study. Rissling O; Glander P; Hambach P; Mai M; Brakemeier S; Klonower D; Halleck F; Singer E; Schrezenmeier EV; Dürr M; Neumayer HH; Budde K Br J Clin Pharmacol; 2015 Nov; 80(5):1086-96. PubMed ID: 25913040 [TBL] [Abstract][Full Text] [Related]
12. Therapeutic drug level monitoring for mycophenolate mofetil: is it justified? Stephan A; Masri MA; Barbari A; Kamel G; Karam A; Kilani H Transplant Proc; 2001 Aug; 33(5):2778-9. PubMed ID: 11498157 [No Abstract] [Full Text] [Related]
13. Pharmacokinetics and pharmacodynamics of mycophenolic acid after enteric-coated mycophenolate versus mycophenolate mofetil in patients with progressive IgA nephritis. Czock D; Rasche FM; Carius A; Glander P; Budde K; Bauer S; Keller F; von Müller L J Clin Pharmacol; 2007 Jul; 47(7):850-9. PubMed ID: 17526858 [TBL] [Abstract][Full Text] [Related]
15. Mycophenolate mofetil pharmacodynamics and pharmacokinetics correlate with rejection score in a BN-to-LEW heterotopic heart transplant model. Klupp J; van Gelder T; Dambrin C; Regieli J; Boeke K; Billingham ME; Morris RE Transplant Proc; 2001 May; 33(3):2170-1. PubMed ID: 11377490 [No Abstract] [Full Text] [Related]
16. IMP-dehydrogenase inhibition in human lymphocytes and lymphoblasts by mycophenolic acid and mycophenolic acid glucuronide. Griesmacher A; Weigel G; Seebacher G; Müller MM Clin Chem; 1997 Dec; 43(12):2312-7. PubMed ID: 9439448 [TBL] [Abstract][Full Text] [Related]
17. Treatment of primary systemic vasculitis with the inosine monophosphate dehydrogenase inhibitor mycophenolic acid. Hiemstra TF; Jones RB; Jayne DR Nephron Clin Pract; 2010; 116(1):c1-10. PubMed ID: 20484933 [TBL] [Abstract][Full Text] [Related]
18. The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Hale MD; Nicholls AJ; Bullingham RE; Hené R; Hoitsma A; Squifflet JP; Weimar W; Vanrenterghem Y; Van de Woude FJ; Verpooten GA Clin Pharmacol Ther; 1998 Dec; 64(6):672-83. PubMed ID: 9871432 [TBL] [Abstract][Full Text] [Related]
19. Mycophenolate mofetil: how to further improve using an already successful drug? van Gelder T Am J Transplant; 2005 Feb; 5(2):199-200. PubMed ID: 15643976 [No Abstract] [Full Text] [Related]